Literature DB >> 26923997

[Scale for assessing negative symptoms in schizophrenia: A systematic review].

C Mach1, S Dollfus2.   

Abstract

INTRODUCTION: Negative symptoms are a fundamental dimension of schizophrenia despite their limited role in the international diagnostic classification. Although a consensual definition seems to be attempted regarding the main negative dimensions (anhedonia, alogia, social withdrawal, blunted affect, avolition), several standardized assessment scales have been created.
OBJECTIVES: The objective of this study was to identify a set of unidimensional instruments which allows an assessment of negative symptoms in schizophrenia and also to identify their general characteristics and the items included.
METHODS: Inclusion criteria were: (a) the unidimensional assessment scales of negative symptoms of schizophrenia; (b) instruments in English (with French versions if possible); (c) all assessment instruments, the oldest and the most recent. The investigation ended in February 2013.
RESULTS: Twelve unidimensional instruments were identified with only one of them based on a self-administered survey (MAP-SR). The number of items included is from 6 (SDS) to 25 (SANS). The fastest instrument is the HEN (5-10min) and the longest is the SANS (30min). The MASS needs an evaluation by another person (family or care-giver). Most instruments need to be handled and take place during a semi-structured or structured psychiatric interview. The SANS allows an assessment of the most important number of negative domains (11 domains). On the other side, we have the MAP-SR (3 domains). The most frequently evaluated domains are emotional blunting, alogia, social withdrawal, anhedonia and avolition. On the other side, we have mood and thought disorders. Only SDS allows to distinguish the primary and secondary negative symptoms. DISCUSSION: The oldest instruments (SANS, NSA-16, SDS) are more complicated to handle and to use. The SANS is the most complete instrument but there are more recent instruments which are easier to use and handle (BNSS, CAINS). Using a self-evaluation survey, MAP-SR is judicious as this type of evaluation is reliable. However, in this case, the assessment covers only a limited part of the negative symptoms.
CONCLUSION: Despite some progress in the definition, assessment and treatment of negative symptoms and despite new scales further instruments which are easy to use in clinical practice and integrating the patient's self-report are needed.
Copyright © 2016 L’Encéphale, Paris. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Assessment; Instruments; Instruments d’évaluation; Negative symptoms; Scales; Schizophrenia; Schizophrénie; Symptômes négatifs

Mesh:

Year:  2016        PMID: 26923997     DOI: 10.1016/j.encep.2015.12.020

Source DB:  PubMed          Journal:  Encephale        ISSN: 0013-7006            Impact factor:   1.291


  3 in total

1.  Validation of the Arabic version of the "self-evaluation of negative symptoms" scale (SNS).

Authors:  Aline Hajj; Souheil Hallit; Karam Chamoun; Hala Sacre; Sahar Obeid; Chadia Haddad; Sonia Dollfus; Lydia Rabbaa Khabbaz
Journal:  BMC Psychiatry       Date:  2020-05-14       Impact factor: 3.630

2.  Examining transcranial random noise stimulation as an add-on treatment for persistent symptoms in schizophrenia (STIM'Zo): a study protocol for a multicentre, double-blind, randomized sham-controlled clinical trial.

Authors:  Jerome Brunelin; Marine Mondino; Julie Haesebaert; Jerome Attal; Michel Benoit; Marie Chupin; Sonia Dollfus; Wissam El-Hage; Filipe Galvao; Renaud Jardri; Pierre Michel Llorca; Laurent Magaud; Marion Plaze; Anne Marie Schott-Pethelaz; Marie-Françoise Suaud-Chagny; David Szekely; Eric Fakra; Emmanuel Poulet
Journal:  Trials       Date:  2021-12-28       Impact factor: 2.279

3.  European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study.

Authors:  Sonia Dollfus; Armida Mucci; Giulia M Giordano; István Bitter; Stephen F Austin; Camille Delouche; Andreas Erfurth; W Wolfgang Fleischhacker; Larisa Movina; Birte Glenthøj; Karoline Gütter; Alex Hofer; Jan Hubenak; Stefan Kaiser; Jan Libiger; Ingrid Melle; Mette Ø Nielsen; Oleg Papsuev; Janusz K Rybakowski; Gabriele Sachs; Alp Üçok; Francesco Brando; Pawel Wojciak; Silvana Galderisi
Journal:  Front Psychiatry       Date:  2022-01-31       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.